Kenvue Inc. Common Stock (KVUE)

17.22
-0.44 (-2.49%)
NYSE · Last Trade: Oct 1st, 4:57 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close17.66
Open17.43
Bid17.22
Ask17.60
Day's Range17.19 - 17.55
52 Week Range14.02 - 20.13
Volume20,680,675
Market Cap-
PE Ratio (TTM)22.36
EPS (TTM)0.8
Dividend & Yield0.8400 (4.88%)
1 Month Average Volume26,597,706

Chart

News & Press Releases

History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.fool.com
Medtronic is following a strategy that has worked well for Johnson & Johnson.
Via The Motley Fool · October 1, 2026
LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion
Nearly half the world’s population is affected by oral disease – and the number of cases is rising. This World Smile Day, LISTERINE® is launching Oral Care Counts – a multiyear education and advocacy initiative showing why oral health is an essential part of overall health and how practical daily habits, including a three-step oral care routine of brushing, flossing and rinsing, can support better oral health. The multiyear education and advocacy campaign is designed to help more people understand the essential role oral health plays in overall health and wellbeing, and how realistic daily habits can make prevention more achievable.
By Kenvue · Via Business Wire · October 1, 2026
Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair
Neutrogena®, Aveeno®, and Regaine®* will present 12 new scientific data sets at the 35th European Academy of Dermatology and Venereology (EADV) Congress taking place September 30th through October 3rd in Vienna.
By Kenvue · Via Business Wire · September 30, 2026
Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signalfool.com
Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.
Via The Motley Fool · September 21, 2026
In today's session, there are S&P500 stocks with remarkable trading volume.chartmill.com
Via Chartmill · September 11, 2026
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?fool.com
One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.
Via The Motley Fool · September 17, 2026
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session.chartmill.com
Via Chartmill · September 15, 2026
These S&P500 stocks are the most active in today's sessionchartmill.com
Via Chartmill · September 14, 2026
Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Nowfool.com
Kenvue's dependable dividend is above average, and it could go even higher if the company is bought by Kimberly-Clark.
Via The Motley Fool · September 14, 2026
Kenvue (NYSE:KVUE) Falls After Q2 Earnings Miss as Kimberly-Clark Deal Loomschartmill.com
Via Chartmill · August 6, 2026
Kimberly Clark is Down 20% From Its 52-Week High. Is the Dip Worth Buying?fool.com
Kimberly Clark is a consumer staples Dividend King with a 5% yield, but it is also undergoing a major business transition.
Via The Motley Fool · September 11, 2026
Curious about the most active S&P500 stocks in today's session?chartmill.com
Via Chartmill · September 11, 2026
Curious about the most active S&P500 stocks in today's session?chartmill.com
Via Chartmill · September 10, 2026
Kenvue Declares Quarterly Cash Dividend
Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is payable on October 2, 2026, to shareholders of record as of the close of business on September 21, 2026.
By Kenvue · Via Business Wire · September 10, 2026
This Dividend King Just Offered a Buy-the-Dip Opportunityfool.com
Deal skepticism and litigation fears still weigh on this consumer staples stalwart.
Via The Motley Fool · August 31, 2026
Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.fool.com
Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.
Via The Motley Fool · August 28, 2026
Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session.chartmill.com
Via Chartmill · August 26, 2026
This Consumer Staples Giant's Dividend Streak Rivals PepsiCo. Nobody Talks About It.fool.com
Kimberly Clark is a lesser-known Dividend King.
Via The Motley Fool · August 24, 2026
2 Dividend Stocks to Buy and Never Sellfool.com
Both of these healthcare leaders are Dividend Kings.
Via The Motley Fool · August 23, 2026
Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Futurefool.com
Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.
Via The Motley Fool · August 20, 2026
Kimberly-Clark (KMB) Q2 2026 Earnings Call Transcriptfool.com
Hsu discusses tariff refunds, China disruptions, and Kenvue integration plans.
Via The Motley Fool · August 11, 2026
Kenvue Reports Second Quarter 2026 Results
Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal second quarter ended June 28, 2026.
By Kenvue · Via Business Wire · August 6, 2026
3 Dividend Stocks That Are No-Brainer Buys for the Second Half of 2026fool.com
As stocks pull back from recent highs, lean into these three blue chip dividend stocks.
Via The Motley Fool · August 2, 2026
Kenvue Increases Quarterly Cash Dividend
Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026.
By Kenvue · Via Business Wire · July 29, 2026
This "Boring" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing Itfool.com
A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.
Via The Motley Fool · July 24, 2026